

## **Operations returning to normal after the cyber attack announced on June 3, 2019**

**24 June 2019**

As communicated in an adhoc press release on Monday June 3<sup>rd</sup>, during the weekend of 1<sup>st</sup>/2<sup>nd</sup> June, Eurofins Scientific (EUFI.PA) was affected by a ransomware attack which caused disruption to many of its IT systems in several countries. Eurofins IT staff and their internal and external IT security teams and experts took prompt actions to contain the incident, mitigate its impact including by taking many systems offline and have been working around the clock to return the IT operations to normal in the companies of the Group that have been affected. As Eurofins IT teams reacted promptly many of the Group's companies were able to continue operating without impacting customers. Moreover, on Tuesday June 4<sup>th</sup> we were able to resume full or partial operations for a number of impacted companies and have continued to do so every day since then. As a result, as of Monday June 17<sup>th</sup>, the vast majority of affected laboratories' operations had been restored. The production and reporting IT systems of essentially all those that remained became operational again during the past week. Restoration operations are continuing for some less important back office and software development systems as well as in a few companies (representing less than 2% of the Group's revenues) some specific procedures required before restart of certain activities that are anticipated to be completed by end of next week.

Eurofins companies have alerted and are cooperating with law enforcement agencies and renowned IT forensics and security companies in the investigation of this matter. Forensics investigations are ongoing but we have identified the variant of the malware used and it is now being recognised and when detected neutralized by our IT security solutions as updated with the versions released on Sunday June 2<sup>nd</sup> and thereafter. Additional security tools we are deploying since then as well as the world class cyber security experts who are supporting us are and will be providing additional protection and monitoring. We are continuing to work intensively with leading cybersecurity experts to further secure our current systems and infrastructure and to add enhanced security features and measures to protect our systems and data. The investigations conducted so far by our internal and external IT forensics experts have not found evidence of any unauthorised theft or transfer of confidential client data. The security of our client data and of all our IT systems is of the utmost importance to Eurofins. Eurofins companies remain committed to making significant investments in the continuous improvement of the security of their IT systems.

Eurofins profoundly apologises to the customers of those of its laboratories and sites that have been impacted by the consequences of this sophisticated attack. As much as possible, the companies concerned have been and will be in communication with customers affected by delays or capacity bottlenecks and are sharing further information as needed and available.

In spite of sometimes significant obstacles, the staff in our laboratories that were affected has been finding countless ways of working to ensure the full or partial continuity of their business and to minimise the impact of this ransomware attack on their customers. The impact of this attack on our financial results may unfortunately be material especially for Q2 but at this point, it is still too early to evaluate the net potential financial impact of this incident on our operations as well as the proportion of revenue losses that will be mitigated by reimbursement from our insurers. It is also too early to evaluate what proportion of the lost work days in the affected companies has already been or can be caught back over the next few days and weeks, including through additional shifts and weekend work. For the above reasons and as many of the affected sites were only partially impacted and their restart to full productivity is typically a progressive process over time, at this time it is not yet possible to provide reliable consolidated information as to the proportion of revenues that will have been affected as a result of this incident. The focus of our teams in the companies that were affected is to catch up on their work backlog and deliver the quality and speed of service our

customers are used to getting from their Eurofins laboratory, and that they deserve. We will provide an update on the financial impact of this attack as part of our half-year report publication on 29<sup>th</sup> of August.

**For more information, please visit [www.eurofins.com](http://www.eurofins.com) or contact:**

Investor Relations  
Eurofins Scientific  
Phone: +32 2 766 1620  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

#### **Notes for the editor:**

##### **Eurofins – a global leader in bio-analysis**

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is a scientific leader in food, environment, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

#### **Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.